Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.5K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.5K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

1.5K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.5K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

579
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
579
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

4.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.8K
Mitral Regurgitation I: Introduction01:20

Mitral Regurgitation I: Introduction

1.2K
Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
1.2K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

1.2K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sustained Reduction in Cardiopulmonary Fitness in Long COVID: A Report from the RECOVER-adult Cohort Study.

JACC. Advances·2026
Same author

Association Between Medicare Drug Plan Ratings and Coverage Barriers for Non-Generic, Evidence-Based Cardiovascular Medications.

Circulation. Population health and outcomes·2026
Same author

Prior Authorization Requirements and Prescription Fill Patterns Among Patients With Heart Failure.

JACC. Advances·2026
Same author

Intrauterine SARS-CoV-2 Exposure and Infant Neurodevelopment through 18 Months of Age: Findings from the Researching COVID to Enhance Recovery (RECOVER) Pregnancy Study.

The Journal of pediatrics·2026
Same author

A dimensional concept analysis on managing life with a left ventricular assist device.

European journal of cardiovascular nursing·2026
Same author

Social Determinants of Health and Pediatric Long COVID in the US.

JAMA pediatrics·2026

Related Experiment Video

Updated: Apr 15, 2026

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents
07:26

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents

Published on: July 14, 2021

5.7K

Reverse Remodeling in Systolic Heart Failure.

Tajinderpal Saraon1, Stuart D Katz

  • 1From the Leon H. Charney Division of Cardiology, New York University Langone Medical Center, New York, NY.

Cardiology in Review
|April 4, 2015
PubMed
Summary

Left ventricular (LV) remodeling involves detrimental changes after heart injury. LV reverse remodeling offers a path to recovery through interventions, improving cardiac function and patient outcomes.

More Related Videos

A Rat Model of Pressure Overload Induced Moderate Remodeling and Systolic Dysfunction as Opposed to Overt Systolic Heart Failure
07:13

A Rat Model of Pressure Overload Induced Moderate Remodeling and Systolic Dysfunction as Opposed to Overt Systolic Heart Failure

Published on: April 30, 2020

7.0K
Permanent Ligation of the Left Anterior Descending Coronary Artery in Mice: A Model of Post-myocardial Infarction Remodelling and Heart Failure
09:37

Permanent Ligation of the Left Anterior Descending Coronary Artery in Mice: A Model of Post-myocardial Infarction Remodelling and Heart Failure

Published on: December 2, 2014

29.0K

Related Experiment Videos

Last Updated: Apr 15, 2026

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents
07:26

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents

Published on: July 14, 2021

5.7K
A Rat Model of Pressure Overload Induced Moderate Remodeling and Systolic Dysfunction as Opposed to Overt Systolic Heart Failure
07:13

A Rat Model of Pressure Overload Induced Moderate Remodeling and Systolic Dysfunction as Opposed to Overt Systolic Heart Failure

Published on: April 30, 2020

7.0K
Permanent Ligation of the Left Anterior Descending Coronary Artery in Mice: A Model of Post-myocardial Infarction Remodelling and Heart Failure
09:37

Permanent Ligation of the Left Anterior Descending Coronary Artery in Mice: A Model of Post-myocardial Infarction Remodelling and Heart Failure

Published on: December 2, 2014

29.0K

Area of Science:

  • Cardiology
  • Heart Failure Research
  • Cardiovascular Medicine

Background:

  • Left ventricular (LV) remodeling describes changes in heart structure and function following injury or altered loading.
  • Progressive LV remodeling increases morbidity and mortality risk due to neurohormonal activation and inflammation.
  • LV reverse remodeling signifies a return towards normal ventricular structure and function.

Purpose of the Study:

  • To review studies demonstrating LV reverse remodeling.
  • To highlight interventions promoting LV reverse remodeling.
  • To discuss future therapeutic targets for improving heart failure outcomes.

Main Methods:

  • Review of selected studies on LV reverse remodeling.
  • Analysis of interventions including pharmacological, pacemaker devices, and mechanical circulatory support.
  • Examination of underlying physiological, neurohormonal, and molecular pathways.

Main Results:

  • Interventions like medications, pacemakers, and mechanical support can induce LV reverse remodeling.
  • Mitigating myocardial injury and neurohormonal/hemodynamic factors are key to reverse remodeling.
  • Successful reverse remodeling leads to improved ventricular structure and function.

Conclusions:

  • LV reverse remodeling is achievable through various therapeutic strategies.
  • Targeting specific pathways offers potential for enhanced heart failure management.
  • Further research into molecular signaling could optimize reverse remodeling therapies.